Cargando…

Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma

BACKGROUND: The role of pretreatment Epstein-Barr virus DNA (pre-DNA) for individualized induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) still remains unknown. We aimed to address this clinical issue. METHODS: In total, data on 6218 patient with newly diagnos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jian, Peng, Hao, Li, Wen-Fei, Zhang, Yuan, Liu, Li-Zhi, Tian, Li, Lin, Ai-Hua, Sun, Ying, Ma, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299978/ https://www.ncbi.nlm.nih.gov/pubmed/30567511 http://dx.doi.org/10.1186/s12885-018-5177-9

Ejemplares similares

Prognostic effect of residual plasma Epstein–Barr viral DNA after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Zheng, Hua, et al.
Publicado: (2023)

Prognostic Value of Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma with Low Pre-treatment Epstein-Barr Virus DNA: a Propensity-matched Analysis
por: Peng, Hao, et al.
Publicado: (2016)

Prognostic Value of Plasma Epstein-Barr Virus DNA Levels Pre- and Post-Neoadjuvant Chemotherapy in Patients With Nasopharyngeal Carcinoma
por: Zhu, Lisheng, et al.
Publicado: (2021)

Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy
por: Peng, Hao, et al.
Publicado: (2016)

Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status
por: Peng, Hao, et al.
Publicado: (2016)

Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein–Barr virus DNA level after induction chemotherapy
por: Liu, Sai-Lan, et al.
Publicado: (2020)

Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein–Barr virus DNA level
por: Liu, Sai-Lan, et al.
Publicado: (2020)

Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy
por: Peng, Hao, et al.
Publicado: (2016)

Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy
por: Zhang, Lu, et al.
Publicado: (2015)

Clinical characteristics and prognostic value of pre‐retreatment plasma epstein‐barr virus DNA in locoregional recurrent nasopharyngeal carcinoma
por: Liu, Ming‐Zhu, et al.
Publicado: (2019)

The role of Epstein–Barr virus in nasopharyngeal carcinoma
por: Su, Zhi Yi, et al.
Publicado: (2023)

Integrating pre- and post-treatment Plasma Epstein-Barr Virus DNA levels for better prognostic prediction of Nasopharyngeal Carcinoma
por: Li, Wanxia, et al.
Publicado: (2021)

Individualized concurrent chemotherapy by pretreatment plasma Epstein‐Barr viral DNA in II‐III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort
por: Sun, Xue‐Song, et al.
Publicado: (2019)

Epstein-Barr virus and nasopharyngeal carcinoma
por: Young, Lawrence S., et al.
Publicado: (2014)

Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma
por: Chan, K.C. Allen
Publicado: (2014)

Positivity of both plasma Epstein–Barr virus DNA and serum Epstein–Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma
por: Zhao, Fei-Peng, et al.
Publicado: (2014)

Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
por: Yao, Ji‐Jin, et al.
Publicado: (2017)

The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma
por: Li, You Quan, et al.
Publicado: (2018)

Impact of Plasma Epstein-Barr Virus-DNA and Tumor Volume on Prognosis of Locally Advanced Nasopharyngeal Carcinoma
por: Chen, Meng, et al.
Publicado: (2015)

Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma
por: Zhang, Yuan, et al.
Publicado: (2016)

Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma
por: Prayongrat, Anussara, et al.
Publicado: (2017)

Role of Epstein-Barr Virus in the Development of Nasopharyngeal Carcinoma
por: Zhang, Hui, et al.
Publicado: (2017)

Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma
por: Hau, Pok Man, et al.
Publicado: (2020)

Plasma Circulating Tumor Epstein–Barr Virus for the Surveillance of Cancer Progression in Bone-Only Metastatic Nasopharyngeal Carcinoma
por: Liu, Guo-Ying, et al.
Publicado: (2022)

The Criteria to Confirm the Role of Epstein-Barr Virus in Nasopharyngeal Carcinoma Initiation
por: Gu, Ai-Di, et al.
Publicado: (2012)

Correlation of nasopharyngeal carcinoma with rare earth elements and the Epstein-Barr virus
por: Zhang, Xiangmin, et al.
Publicado: (2018)

Epstein–Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma
por: Xiang, Zhong‐zheng, et al.
Publicado: (2022)

The impact of plasma epstein–barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study
por: Tang, L-Q, et al.
Publicado: (2014)

Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population
por: Chen, Wen-Jie, et al.
Publicado: (2021)

Roles of Inflammasomes in Epstein–Barr Virus-Associated Nasopharyngeal Cancer
por: Looi, Chin King, et al.
Publicado: (2021)

Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Li, Wen-Fei, et al.
Publicado: (2016)

Radiotherapy Alone Versus Concurrent or Adjuvant Chemoradiotherapy for Nasopharyngeal Carcinoma Patients with Negative Epstein–Barr Virus DNA after Induction Chemotherapy
por: Kong, Fangfang, et al.
Publicado: (2023)

The Effect of Adding Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Undetectable Pretreatment Epstein-Barr Virus DNA
por: Jin, Ya-Nan, et al.
Publicado: (2017)

Can Epstein–Barr virus‐deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
por: Zhang, Qun, et al.
Publicado: (2022)

IgA antibodies to Epstein-Barr viral capsid antigens in saliva of nasopharyngeal carcinoma patients.
por: Ho, H. C., et al.
Publicado: (1977)

Prognostic Value of Oral Epstein–Barr Virus DNA Load in Locoregionally Advanced Nasopharyngeal Carcinoma
por: He, Yong-Qiao, et al.
Publicado: (2022)

Association of Epstein-Barr virus infection with peripheral immune parameters and clinical outcome in advanced nasopharyngeal carcinoma
por: Tao, Dan, et al.
Publicado: (2020)

Establishment of a Prognostic Nomogram for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Incorporating TNM Stage, Post-Induction Chemotherapy Tumor Volume and Epstein-Barr Virus DNA Load
por: Jiang, Yu-Ting, et al.
Publicado: (2021)

Integration Profiling Between Plasma Lipidomics, Epstein–Barr Virus and Clinical Phenomes in Nasopharyngeal Carcinoma Patients
por: Huang, Yi, et al.
Publicado: (2022)

CD47 Overexpression Is Associated with Epstein–Barr Virus Infection and Poor Prognosis in Patients with Nasopharyngeal Carcinoma
por: Wang, Zhi-Hui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g6tiu8skishnn32rmno9mkui61